Results 191 to 200 of about 16,526 (218)

Anidulafungin, a New Echinocandin

Drugs, 2009
Anidulafungin is a new echinocandin with potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole and amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including azole-refractory disease.
openaire   +3 more sources

Echinocandins

2021
Alexander J. Lepak, David R. Andes
openaire   +1 more source

Candida parapsilosis isolates carrying mutations outside FKS1 hotspot regions confer high echinocandin tolerance and facilitate the development of echinocandin resistance

International Journal of Antimicrobial Agents, 2023
Amir Arastehfar, Lisa Lombardi, Ulrike Binder   +2 more
exaly  

Echinocandins

2009
David S. Perlin, William W. Hope
openaire   +1 more source

Echinocandins

Infectious Diseases in Clinical Practice, 2005
openaire   +1 more source

Pan-Echinocandin Resistant C. parapsilosis Harboring an F652S Fks1 Alteration in a Patient with Prolonged Echinocandin Therapy

Journal of Fungi (Basel, Switzerland), 2022
Maria Siopi, Anastasia I Spiliopoulou, Fotini Paliogianni   +2 more
exaly  

[Echinocandins: Applied pharmacology].

Revista iberoamericana de micologia, 2017
The echinocandins share pharmacodynamic properties, although there are some interesting differences in their pharmacokinetic behaviour in the clinical practice. They are not absorbed by the oral route. They have a somewhat special distribution in the organism, as some of them can reach high intracellular concentrations while, with some others, the ...
openaire   +1 more source

Echinocandins

2010
Andreas H. Groll, Dominik Schrey, Thomas J. Walsh   +2 more
openaire   +1 more source

Echinocandins

  +4 more sources

Resistance to echinocandin-class antifungal drugs

Drug Resistance Updates, 2007
David S Perlin
exaly